Opinion

Video

EMPOWER-Lung3: Cemiplimab Plus Chemotherapy in Advanced NSCLC

Author(s):

Edgardo S. Santos, MD, FACP, FCCP

Edgardo Santos, MD, FACP, FCCP, analyzes the influence on clinical practice arising from the application of cemiplimab with chemotherapy in advanced non-small cell lung cancer (NSCLC) observed in the EMPOWER-Lung3 trial.

Related Videos
Paul Chinfai Lee, MD, discusses the role of surgeons in regard to molecular testing in non–small cell lung cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on biomarker testing in metastatic or resectable non–small cell lung cancer.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Noman Ashraf, MD
Ivy Riano, MD, of Dartmouth Geisel School of Medicine
Daniel E. Haggstrom, MD
Related Content
OncLive's Top 5 Stories of the Week in Oncology
November 9th 2024

The OncFive: Top Oncology Articles for the Week of 11/3

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Jacob Sands, MD, of Dana-Farber Cancer Institute
November 8th 2024

Frontline Vibostolimab/Pembrolizumab Plus Chemo Meets Futility Threshold in ES-SCLC

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
October 7th 2024

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

Lung Cancer - stock.adobe.com
November 8th 2024

FDA Approval Sought for Sunvozertinib in Pretreated EGFR Exon 20+ Advanced NSCLC

Lung Cancer
November 7th 2024

Siglec-15 Represents Potential Therapeutic Target in NSCLC, Other Solid Tumors